ArticleDrug design, development and therapy2025
Xian Huang Fang Inhibits the PKCδ/MAPK Signaling Pathway to Attenuate Renal Tubular Epithelial Cell Senescence and Thereby Delay Renal Interstitial Fibrosis.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cellular senescence of renal tubular epithelial cells in diabetic kidney disease: emerging mechanisms and targeted interventions.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Chinese herbal medicine compound Xian Huang Fang (XHF) protects renal function and delays the progression of chronic kidney disease (CKD). Currently, XHF has been found to alleviate renal interstitial fibrosis, but the specific mechanism is still unclear, and its underlying molecular mechanism needs to be further elucidated. Purpose: The objective of this study was to investigate the protective effects of XHF against renal fibrosis and the underlying mechanisms. Methods: Chemical profiling of the reconstituted XHF freeze-dried powder was performed using ultra-high-performance liquid chromatography coupled with quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS). Chronic renal failure model was established via 5/6 nephrectomy (A/I), and renal tubular epithelial (HK-2) cell fibrosis was induced by 5 ng/mL Transforming growth factor β1 (TGF-β1). Mechanisms were evaluated using network pharmacology, histopathology, Western blotting, immunofluorescence (IF), and senescence-associated β-galactosidase (SA-β-gal) staining. Results: XHF significantly ameliorated renal injury, reduced inflammatory infiltration in the renal interstitium, and effectively improved renal interstitial fibrosis (RIF) in 5/6 nephrectomy (A/I) model rats. Network analysis revealed Protein Kinase C delta (PKCδ) as a key target; XHF inhibited the phosphorylation of PKCδ (Tyr311), subsequently downregulating phosphorylated (p)-p38, p-ERK, p-JNK, and p-NF-κB both in vivo and in vitro. Furthermore, it upregulated the expression of the cell proliferation marker Ki67, while suppressing senescence markers (SA-β-gal activity, p21) and the senescence-associated secretory phenotype (SASP) factors (eg, IL-6). Conclusion: XHF alleviates renal interstitial fibrosis by inhibiting the PKCδ/MAPK signaling pathway, thereby reducing the senescence of renal tubular epithelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.